Silpa-Archa et al. (2019) [28] identified insulin therapy as the only significant risk factor for POE in people with diabetes, suggesting that further investigation into perioperative glycemic markers, such as preoperative glycated hemoglobin (HbA1c) and postoperative fasting plasma glucose levels, is warranted to better elucidate the role of glycemic control in POE risk. The gene discussed is INS; the disease is diabetes mellitus.